TROP2 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P09758 |
---|---|
Clone Names | 81028125 |
Gene ID | 4070 |
---|---|
Other Names | Tumor-associated calcium signal transducer 2, Cell surface glycoprotein Trop-2, Membrane component chromosome 1 surface marker 1, Pancreatic carcinoma marker protein GA733-1, TACSTD2, GA733-1, M1S1, TROP2 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6681c was selected from the Center region of human TROP2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | TACSTD2 |
---|---|
Synonyms | GA733-1, M1S1, TROP2 |
Function | May function as a growth factor receptor. |
Cellular Location | Membrane; Single-pass type I membrane protein. |
Tissue Location | Placenta, pancreatic carcinoma cell lines. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
TROP2 is a carcinoma-associated antigen defined by the monoclonal antibody GA733. This antigen is a member of a family including at least two type I membrane proteins. It transduces an intracellular calcium signal and acts as a cell surface receptor. Mutations of its gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.
References
Goldstein,A.S., Proc. Natl. Acad. Sci. U.S.A. 105 (52), 20882-20887 (2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.